Determination of COVID-19 Related Virus in Central Nervous System

Determination of SARS-Cov-2 Virus in Central Nervous System

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04775784

Enrollment

300

Registered

2021-03-01

Start date

2020-12-17

Completion date

2023-12-31

Last updated

2023-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CNS Disease, CNS Infection, COVID-19 Testing

Keywords

SARS-Cov-2, CNS infection, Coronavirus, Brain

Brief summary

Coronavirus disease 2019 (COVID-19) is a highly infectious pandemic disease caused by SARS-CoV-2 virus. Central Nervous System (CNS) complications associated with COVID-19 might be secondary sequelae due to exuberant systemic innate-mediated hyper-inflammation, which may impair neurovascular endothelial function, disrupt blood brain barrier (BBB), activates CNS innate immune signaling pathways, and induces parainfectious autoimmunity, potentially contributing to the CNS manifestations. Although the predominant clinical manifestation of SARS-CoV-2 is characterized by dyspnea, unremitting fever and hypoxemic respiratory failure, neurologic manifestations do occur in most hospitalized SARS-CoV-2 patients and include non-specific encephalopathy, psychosis, meningitis/encephalitis, myelitis, cerebrovascular events, Guillain-Barre' syndrome, and cranial or peripheral neuropathies, such as anosmia and ageusia. To date, data about primary CNS involvement due to neurotropism and direct neuroinvasion are still lacking.

Detailed description

Determination of SARS-CoV-2 presence in central nervous system

Interventions

DIAGNOSTIC_TESTDetermination of SARS-CoV2 presence in CNS

Brain tissue sampling

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Adult patients * Patients candidate for CNS surgery * Patients who have been tested for nasopharyngeal swab for SARS-CoV-2 * Patients who have been tested for serology test for anti SARS-CoV-2 immunoglobulinG (IgG) and immunoglobulinM (IgM) antibodies * Patients able to sign informed consent

Exclusion criteria

* Patients not meeting inclusion criteria

Design outcomes

Primary

Measure	Time frame	Description
Determination of SARS-CoV-2 presence in the CNS	Surgery	Brain tissue sampling analysis

Countries

Italy

Contacts

Primary ContactLaura Sincinelli

sincinelli.laura@hsr.it00390226435568

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026